Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and HyperkalaemiaCompleted
NCT04566653N/AUpdated Nov 7, 2023
Sponsor: AstraZeneca
Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
United States, Canada, France, Italy, Spain +1 more
Chinese Multiple Dose Escalation (MDE) High Dose StudyCompleted
NCT05437848Phase 1Updated Nov 7, 2023
Sponsor: AstraZeneca
Diabetes
China
Olaparib and Radiotherapy in Head and Neck CancerUnknown
NCT02229656Phase 1Updated Nov 7, 2023
Sponsor: The Netherlands Cancer Institute
Laryngeal Cancer Stage II · Laryngeal Cancer Stage III · Carcinoma, Squamous Cell · Head and Neck Neoplasms
Netherlands
Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese AdultsCompleted
NCT04840849Phase 1Updated Nov 2, 2023
Sponsor: AstraZeneca
Evaluate PK Profile
China
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung CancerTerminated
NCT03871153Phase 2Updated Nov 1, 2023
Sponsor: Greg Durm, MD
Non Small Cell Lung Cancer · Stage III Non-small-cell Lung Cancer
United States
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.Completed
NCT01750281Phase 2Updated Oct 24, 2023
Sponsor: AstraZeneca
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
United States, Brazil, Bulgaria, France, Germany +3 more
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT TrialWithdrawn
NCT05161533Phase 2Updated Oct 18, 2023
Sponsor: University of Washington
Extensive Stage Lung Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8 · Stage IVA Lung Cancer AJCC v8 · Stage IVB Lung Cancer AJCC v8
United States
Exacerbations and Their Outcomes International (EXACOS International)Completed
NCT04928417N/AUpdated Oct 18, 2023
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
Chile, Mexico, Russia, Taiwan
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid TumorsCompleted
NCT02718911Phase 1Updated Oct 16, 2023
Sponsor: Eli Lilly and Company
Solid Tumor
United States, Belgium, Czechia, Israel
A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy VolunteersCompleted
NCT04198558Phase 1Updated Oct 16, 2023
Sponsor: AstraZeneca
Chronic Pain
Germany
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the PancreasTerminated
NCT03490760Phase 2Updated Oct 12, 2023
Sponsor: Baptist Health South Florida
Adenocarcinoma of the Pancreas
United States
PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.Recruiting
NCT05306743NAUpdated Oct 12, 2023
Sponsor: Observational and Pragmatic Research Institute
Chronic Obstructive Pulmonary Disease
United States
Better Diabetes Control, Quality - Educate to Achieve Compliance.Completed
NCT01728714N/AUpdated Oct 12, 2023
Sponsor: AstraZeneca
Diabetes Type 2
Portugal
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung CancerCompleted
NCT02904954Phase 2Updated Oct 11, 2023
Sponsor: Weill Medical College of Cornell University
Carcinoma, Non-Small-Cell Lung
United States
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerCompleted
NCT02125461Phase 3Updated Oct 10, 2023
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Australia, Belgium, Canada, Chile +21 more
Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.Unknown
NCT04737382NAUpdated Oct 10, 2023
Sponsor: The Netherlands Cancer Institute
Non-small-cell Lung Carcinoma
Netherlands
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney DiseaseTerminated
NCT04727528Phase 3Updated Oct 6, 2023
Sponsor: AstraZeneca
Hyperkalaemia · Metabolic Acidosis · Chronic Kidney Disease
United States, Puerto Rico
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)Completed
NCT02987543Phase 3Updated Oct 6, 2023
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
United States, Argentina, Australia, Austria, Brazil +15 more
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompleted
NCT02272790Phase 2Updated Oct 3, 2023
Sponsor: AstraZeneca
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
United States, Canada, Netherlands
Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United KingdomCompleted
NCT04667312N/AUpdated Oct 2, 2023
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer NSCLC
United Kingdom
Preventing Anaphylaxis With AcalabrutinibCompleted
NCT05038904Phase 2Updated Sep 28, 2023
Sponsor: Johns Hopkins University
Food Allergy · Food Allergy Peanut
United States
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic DermatitisCompleted
NCT04212169Phase 2Updated Sep 28, 2023
Sponsor: AstraZeneca
Atopic Dermatitis
United States, Australia, Germany, Poland, Spain +1 more
Determination of Prevalence and Features of HRRm mCRPC (ADAM)Completed
NCT04712890N/AUpdated Sep 28, 2023
Sponsor: AstraZeneca
HRRm mCRPC
Russia
Long-term Observational Study of the Safety of RoflumilastCompleted
NCT03381573N/AUpdated Sep 26, 2023
Sponsor: AstraZeneca
COPD
United States, Germany, Norway, Sweden
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 StatusCompleted
NCT05217381N/AUpdated Sep 25, 2023
Sponsor: MedSIR
Early Breast Cancer · Metastatic Breast Cancer · Locally Advanced Breast Cancer
Spain

Previous page Next page